Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.56 |
| ▸ | HPGD | P15428 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | EIF4A3 | P38919 | 2/20 | 0.53 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.49 |
| ▸ | RHEB | Q15382 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30817101 | 1.00 | HSD17B10 (0.56) | HSD17B10HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL27523308 | 0.84 | EIF4A3 (0.68) | HSD17B10HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL27896963 | 0.83 | HPGD (0.53) | HSD17B10HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL28740680 | 0.83 | HPGD (0.53) | HSD17B10HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL27530562 | 0.83 | HPGD (0.53) | HSD17B10HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL3599395 | 0.83 | EIF4A3 (0.57) | HSD17B10HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL3605104 | 0.83 | HPGD (0.53) | HSD17B10HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL27527790 | 0.83 | HPGD (0.53) | HSD17B10HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL8985835 | 0.80 | HPGD (0.60) | HSD17B10HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL4043989 | 0.79 | CDK1 (0.56) | HSD17B10HPGDALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346592-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION | 2025-11-13 | — | — | US | disclosed |
| EP-4531849-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024059087-A1 | 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023230609-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2023-11-30 | — | — | WO | disclosed |
| US-8202993-B2 | 5-bromo-1'-[(6-bromo-1H-indol-2-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(1H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8071622-B2 | 1-[1-(6-Methoxy-1H-indole-2-carbonyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-7799923-B2 | Vasopressin receptor antagonists; (4-Benzotriazol-1-yl-piperidin-1-yl)-(5-chloro-1H-indol-2-yl)-methanone; antidepressants, anxiolytic agents; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2089381-B1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| EP-2102207-B1 | SPIRO-PIPERIDINE DERIVATIVES AS VIA RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-06-02 | — | — | EP | disclosed |
| CN-101547923-A | Spiro-piperidine derivatives as VIA receptor antagonists | HOFFMANN LA ROCHE (CH) | 2009-09-30 | — | — | CN | disclosed |
| US-20080269290-A1 | Indoles | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20080146568-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2008068185-A1 | SPIRO-PIPERIDINE DERIVATIVES AS VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139618-A1 | INDOLES | HOFFMAN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008068184-A1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139554-A1 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-06-12 | — | — | US | disclosed |
| US-20080139548-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| US-20080139553-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139617-A1 | INDOLES | HOFFMAN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2004108671-A1 | SUBSTITUTED INDOLES WITH SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139553-A1 | SPIRO-PIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | HSD17B10 3506/4885HPGD 1402/4885ALDH1A1 275/4885 |
| US-20080139548-A1 | INDOLES | HTR1A, AVPR1A, TPH1 | HSD17B10 3189/4885HPGD 1713/4885ALDH1A1 397/4885 |
| US-20080139554-A1 | SPIRO-PIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | HSD17B10 3506/4885HPGD 1402/4885ALDH1A1 275/4885 |
| US-20080139617-A1 | INDOLES | HTR1A, AVPR1A, TPH1 | HSD17B10 3189/4885HPGD 1713/4885ALDH1A1 397/4885 |
| US-20080269290-A1 | Indoles | HTR1A, AVPR1A, TPH1 | HSD17B10 3189/4885HPGD 1713/4885ALDH1A1 397/4885 |
| US-20080139618-A1 | INDOLES | HTR1A, AVPR1A, TPH1 | HSD17B10 3189/4885HPGD 1713/4885ALDH1A1 397/4885 |
| US-20250346592-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI6, PADI2 | HSD17B10 449/4885HPGD 409/4885ALDH1A1 183/4885 |
| US-20080146568-A1 | SPIRO-PIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | HSD17B10 3506/4885HPGD 1402/4885ALDH1A1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.